1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Achiko AG
  6. News
  7. Summary
    ACHI   CH0522213468

ACHIKO AG

(ACHI)
  Report
Delayed Swiss Exchange  -  05/20 11:30:39 am EDT
0.1140 CHF   +8.57%
05/19Achiko Preliminarily Expects FY21 Loss as Annual Report Delayed by Pandemic, Staffing
MT
05/19Achiko AG Reports Key Unaudited Financial Results for the Year Ended December 31, 2021
AQ
05/19Achiko AG Reports Key Unaudited Financial Results for the Year Ended 31 December 2021
EQ
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Achiko AG Announces Feature Article on How We Get Back to Normal with its AptameXTM Covid-19 Rapid Test Technology

01/17/2022 | 08:10am EDT

EQS-News: Achiko AG / Key word(s): Miscellaneous
Achiko AG Announces Feature Article on How We Get Back to Normal with its AptameXTM Covid-19 Rapid Test Technology

17.01.2022 / 14:08


Achiko AG Announces Feature Article on How We Get Back to Normal with its AptameXTM Covid-19 Rapid Test Technology

Zurich, 17 January 2022- Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) ("Achiko", the "Company") is pleased to announce a feature article in The Jakarta Post: "How we get back to normal: Restoring Trust and Confidence through Testing with AptameX" which discusses how Achiko is contributing to provide affordable and accurate testing to Indonesia with its Covid-19 saliva-based rapid test AptameX(TM), which fills the gap between rapid tests and PCR testing.

The article is available at this link: https://www.thejakartapost.com/adv-longform/2022/01/17/how-we-get-back-to-normal-restoring-trust-and-confidence-through-testing-with-aptamex.html and within the News section of Achiko's web site: https://www.achiko.com/news.

ABOUT ACHIKO AG
Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) is developing disruptive diagnostic solutions that puts people first. The company's lead product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. The test and companion app were launched in Indonesia in mid-2021 and an application for CE Mark approval in Europe will be submitted in 2022.

Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameXTM and companion health apps via its digital mobile health technology division, Teman SehatTM. The AptameX DNA aptamer tests can be rapidly chemically synthesized, are cost-effective and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.

Headquartered in Zurich, Achiko has offices in Hong Kong, Jakarta, Seoul and Singapore.

Media contacts:

ACHIKO AG
Investor Relations
E: ir@achiko.com

Switzerland & Global
Marcus Balogh
Farner Consulting Ltd.
E: achiko@farner.ch
T: +41 44 266 67 67

U.S. & Global
Jeanene Timberlake
RooneyPartners
E: jtimberlake@rooneypartners.com
T: +1 646 770 8858

Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties, and other factors, which could cause the actual results, financial condition, performance, or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.



End of Media Release


Language: English
Company: Achiko AG
Tessinerplatz 7
8002 Zurich
Switzerland
E-mail: ir@achiko.com
Internet: https://www.achiko.com/
ISIN: CH0522213468
Valor: 48788430
Listed: SIX Swiss Exchange
EQS News ID: 1269554

 
End of News EQS News Service

1269554  17.01.2022 

fncls.ssp?fn=show_t_gif&application_id=1269554&application_name=news&site_id=zonebourse_sftp

© EQS 2022
All news about ACHIKO AG
05/19Achiko Preliminarily Expects FY21 Loss as Annual Report Delayed by Pandemic, Staffing
MT
05/19Achiko AG Reports Key Unaudited Financial Results for the Year Ended December 31, 2021
AQ
05/19Achiko AG Reports Key Unaudited Financial Results for the Year Ended 31 December 2021
EQ
05/19Achiko AG Reports Key Unaudited Financial Results for the Year Ended 31 December 2021
EQ
05/17Achiko AG Obtains CE Mark for AptameX™ Covid-19 Rapid Test
AQ
05/17Achiko Receives CE Mark For COVID-19 Rapid Test Allowing Sales In EU Countries
MT
05/17Achiko AG Obtains CE Mark for AptameXTM Covid-19 Rapid Test
EQ
05/17Achiko AG Secures Contract Manufacturing with Key Vendors in Taiwan
CI
05/17Achiko AG Expects to Have AptameX in Widespread Commercial Availability in Third Quarte..
CI
04/29Achiko AG – Publication of Annual Report and Annual Financial Statements 2021 to ..
AQ
More news
Analyst Recommendations on ACHIKO AG
More recommendations
Financials (USD)
Sales 2020 2,81 M - -
Net income 2020 -14,1 M - -
Net Debt 2020 1,57 M - -
P/E ratio 2020 -2,61x
Yield 2020 -
Capitalization 15,5 M 15,5 M -
EV / Sales 2019 -
EV / Sales 2020 14,0x
Nbr of Employees 29
Free-Float 63,9%
Chart ACHIKO AG
Duration : Period :
Achiko AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACHIKO AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Managers and Directors
Steven Goh Chief Executive Officer & Director
Morris S. Berrie President
Adam O’Keeffe Chief Financial Officer
Yao Bian Wu Chairman
Ann Chow Head-Investor Relations
Sector and Competitors
1st jan.Capi. (M$)
ACHIKO AG-34.48%16
INTUIT INC.-42.82%104 013
FIDELITY NATIONAL INFORMATION SERVICES, INC.-8.68%60 878
ADYEN N.V.-36.58%47 897
WORLDLINE-23.77%11 058
KAKAO PAY CORP.-45.79%9 798